CYTKCytokinetics, Incorporated

$8B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+89.1% YoY

Gross Profit

-$98M-6223.1% margin

Operating Income

-$156M-9856.3% margin

Net Income

-$161M-10220.1% margin

EPS (Diluted)

$-1.36

QoQ Revenue Growth

-90.7%

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$137M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.5B

Stockholders' Equity

-$266M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$835,000	+89.1%
Gross Profit	-$98M	-$81M	-21.7%
Operating Income	-$156M	-$126M	-23.3%
Net Income	-$161M	-$136M	-19.0%

CYTK Q1 2025 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena